The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE^−/− Mice

Figure 1

Changes of metabolic parameters in mice from each group. (a) and (c) Compared with non-DM group, the blood glucose in DM group was significantly increased; and dapagliflozin treatment of 12 wks significantly decreased blood glucose in both groups; (b) and (d) no significant changes of body weight were detected before and after dapagliflozin treatment in each group; (e), (g), and (h) the levels of cholesterol were significantly increased in the ApoE^−/− mice fed with a high-fat diet, particularly in DM ApoE^−/− mice. Dapagliflozin treatment did not reduce the levels of TCH, HDL-c, or LDL-c; (f) and (i): dapagliflozin treatment decreased the levels of TG and FFA. , ; , ; ##, .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)